Table 3.

Multivariate linear regression analyses for the changes in TMAO-related metabolites after rosuvastatin therapy (n = 112)

Variables	TMAO b		Choline b		Carnitine b		Betaine b		GBB b
	B	P	B	P	B	P	B	P	B	P
Sex	−0.198	0.618	− 0.939	0.080	−2.422	0.292	1.232	0.542	−0.012	0.024
Age	0.027	0.380	0.065	0.111	−0.122	0.488	−0.006	0.971	0.000	0.702
BMI	−0.010	0.854	0.007	0.923	−0.070	0.825	−0.072	0.802	0.001	0.437
eGFR	−0.037	0.276	0.059	0.188	−0.055	0.775	0.224	0.187	0.000	0.993
TMAO a	0.386	< 0.001
Choline a			0.355	< 0.001
Carnitine a					0.371	< 0.001
Betaine a							0.756	< 0.001
GBB a									0.715	< 0.001

^aindicates before rosuvastatin therapy

^bindicates after rosuvastatin therapy

TMAO Trimethylamine N-oxide, BMI Body mass index, eGFR Estimated glomerular filtration rate, GBB γ-butyrobetaine. Variables including sex, age, BMI and eGFR were entered into the multivariate linear regression model.